1 month ago
Hepatitis B: Early Treatment Urgent for Millions in India
Hepatitis B is a serious liver infection that can stay hidden for years without symptoms.
In India, millions of people have it, but most don't get treated early enough.
This can lead to severe liver damage or even death.
New guidelines suggest treating everyone with the virus, not just those with obvious symptoms.
This is important because early treatment can prevent serious problems later.
However, there's also a big issue of stigma and discrimination against people with hepatitis B. Changing mindsets and ensuring early treatment is crucial to saving lives and improving the quality of life for those affected.
Hepatitis B can remain silent but cause severe liver damage or cancer in 10% of infected individuals.
In India, 29 million people live with hepatitis B, but only 3-5% receive antiviral treatment.
New Asian guidelines recommend treating anyone with detectable hepatitis B DNA and above normal liver enzyme levels.
Stigma and discrimination against hepatitis B patients are significant barriers to early treatment and testing.
Early treatment can prevent liver damage, cancer, and premature death, and should be part of national policy.
- Who
- Millions of Indians living with hepatitis B, including Anand, a 37-year-old engineer
- What
- The urgent need for early treatment of hepatitis B to prevent severe complications and deaths
- Where
- India, with a significant hepatitis B burden
- When
- Anand was diagnosed 12 years ago; new Asian guidelines released in June 2026
- Why
- To prevent cirrhosis, liver failure, and liver cancer, and to reduce stigma and discrimination
Current Treatment Guidelines
New Asian Guidelines
Treatment Criteria
Current Treatment Guidelines
Treatment only for high viral load, raised liver enzymes, or liver scarring
New Asian Guidelines
Treatment for any detectable hepatitis B DNA and above normal liver enzyme levels, irrespective of scarring
Treatment Approach
Current Treatment Guidelines
Selective treatment based on specific criteria
New Asian Guidelines
Universal 'Treat All' approach
Key facts
- Global Deaths in 2024
- 1.1 million
- Increase in Deaths Since 2015
- 17%
- Infected in India
- 29 million
- Treatment Rate in India
- 3-5%
- Cost of Antivirals in India
- Less than Rs 1,000/month
- Treatment Adherence Rate
- More than 75%







